- 中文名稱
RELB 一抗
- 英文名字
- RELB Primary antibody
- 供應商
- Promab
- 產品貨號
- PMB-30663
- 產品報價
- ¥詢價/100ul

- 產品說明書
- 點擊查看
- 購買方式
- Promab中國區現貨中心已經建立,95%產品中國有現貨庫存。銀行轉賬、電匯、支票、現金,在線支付寶及網銀支付,或直接與我們電話聯系。本公司所有產品僅供科研使用,不用于臨床診斷。
- 產品新聞

- 背景資料
- NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49. As a member of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment
- 應用類型
- IHC,ICC,FCM
- 免疫原
- Purified recombinant fragment of human RELB (AA: 273-443) expressed in E. Coli.
- 來源宿主
- Mouse
- 反應性
- Human
- 保存建議
- 4℃短期保存;-20℃長期保存。避免凍融循環。
- 其他
- ProMab 生物技術公司通過整合生物信息學、分子生物學、蛋白質表達、純化技術、基因克隆、微生物學和免疫學,利用新型高通量技術開發重組蛋白、抗體和工程細胞系并將其商業化。專注于免疫治療領域,特別是 CAR-T/NK 細胞技術。ProMab 還開發了一種新型的 mRNA 脂質納米顆粒(mRNA-LNP)平臺,用于即用型試劑和定制研究服務,以推進現有產品并擴展到更多的研究領域。

- 注意
-
該頁面的中文產品信息的翻譯,僅供參考。準確的產品信息請以廠家的英文說明書為準。下單前,請瀏覽說明書確認。
-